N/A N=1,918 FluSAFE: Flu SMS Alerts to Freeze Exposure
Influenza · Acute Respiratory Infection · Influenza-like Illness
Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=178 Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
Influenza Virus Infection Transmission in Humans
Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number
Phase 4 N=29,255 Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
Influenza
Primary: MAARI Rate During the Epidemic Period (2007-2008) — 12503; 18998 Number of MAARI
Phase 2 N=326 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
N/A N=544 Feasibility of Cocooning Immunization Strategy With Influenza Vaccine
Influenza
Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants
Phase 4 N=165 Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants
N/A N=30,537 TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations
Influenza
Primary: Influenza Immunization: Pediatric — 43.6; 39.9 % participant vaccinated with influenza
Phase 3 N=7,250 Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Influenza
Primary: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains…
N/A N=558 Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
Influenza, Human
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…
Phase 3 N=64 Zanamivir Versus Trivalent Split Virus Influenza Vaccine
Influenza
Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25
Phase 2 N=385 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population
Influenza · Influenza Vaccines
Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer
N/A N=4,561 Influenza Resistance Information Study
Influenza
Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants
Phase 3 N=3,670 Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)
Influenza
Primary: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens — 35; 62 Participants
Phase 2 N=59 The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
Influenza
Primary: Mean Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge — 16.09; 10.70 log[10] copies/milliliter (mL)*hour — p=0.0390
Phase 1 N=50 Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults
Influenza
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration — 4; 3; 7; 9 Participants
Phase 1 N=25 Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults
Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H10ssF-6473 Product Administration — 3; 9; 5; 17 Participants
N/A N=216 Improving Communication During a Pandemic Flu Outbreak
Healthy
Primary: Change in Intentions to Take Antivirals for Pandemic Flu — 8.29; 8.16; 8.23; 8.35 score on a scale — p=>.05
Phase 1 N=45 Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
Influenza
Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Phase 1 N=52 Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults
Influenza Infection
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration — 5; 8; 11; 9 Participants
Phase 2 N=74 Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People
Influenza
Primary: Number of Patients With Mild to Moderate Influenza Disease (MMID) — 6; 29 participants
Phase 2 N=153 Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model
Influenza
Primary: Number of Participants With Mild to Moderate Influenza Disease (MMID) — 23; 13; 15; 19 Participants — p=0.03
N/A N=7,645 Surveillance for Adverse Events Following Influenza Immunization
Influenza · Vaccines Adverse Reaction
Primary: Number of Participants Who Had Experienced a New Health Problem or the Worsening of an Existing Health Condition That Resulted in a Medical Consultation — 153 participants
Phase 3 N=5,071 Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above
Influenza
Primary: Number of Subjects With Solicited Local Symptoms — 212; 16; 39; 3 Participants
Phase 4 N=292 Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home
Influenza
Primary: Number of Participants Who Received Influenza Vaccine. — 250 participants
Phase 3 N=329 Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
Influenza A · Influenza B
Primary: Number of Patients in Each of 6 Clinical Status Categories on Day 7 — 3; 2; 6; 11 Participants — p=.33
Phase 2 N=66 Study Examining PrEP-001 in Healthy Subjects
Influenza A H3N2
Primary: Primary Efficacy Endpoint: The Area Under the Curve (AUC) of Total Symptom Score From Day 1 (Post Viral Challenge) to Day 8 (Quarantine Discharge). — 17956.5; 4502.6…
Phase 2 N=630 Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
Influenza
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs — 40; 50 percentage of participants analyzed — p=0.046
N/A N=80,452 High-risk Influenza Vaccine Alert
Influenza
Primary: Flu Vaccination — 4459; 4456; 4575 Participants — p=0.517
Phase 2 N=145 Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model
Influenza
Primary: Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR — 649.7; 726.1; 646.5; 726.1 hour*Log10 Viral Particles/ ml — p=0.1711